

## A-V Search Hysteresis in Dual-Chamber Pacemakers

### SUMMARY

This article provides an overview of the A-V Search Hysteresis (AVSH) feature available in many Boston Scientific pacemakers. This overview includes:

- How AVSH works
- How AVSH can encourage AV conduction and help reduce RV pacing
- Parameters associated with AVSH
- Considerations for programming an extended AV Delay

### CRM PRODUCTS REFERENCED

The following are trademarks of Cardiac Pacemakers Inc., a Boston Scientific company: ALTRUA, INSIGNIA I Plus/, INSIGNIA AVT, INSIGNIA Ultra, PULSAR MAX II, PULSAR MAX, PULSAR.

Products referenced herein may not be approved in all geographies. For comprehensive information regarding device operation, please reference the appropriate product labeling.

### CRM CONTACT INFORMATION

#### United States

[www.bostonscientific.com](http://www.bostonscientific.com)

Technical Services – U.S.  
LATITUDE Clinician Support – U.S.

1.800.CARDIAC (227.3422)  
+1.651.582.4000  
tech.services@bsci.com  
latitude@bsci.com

Patient Services  
1.866.484.3268

#### International

[www.bostonscientific-international.com](http://www.bostonscientific-international.com)

Technical Services – Europe  
+32 2 416 7222  
eurtechservice@bsci.com

International LATITUDE Customer Support  
[www.latitude.bostonscientific-international.com](http://www.latitude.bostonscientific-international.com)  
latitude.international@bsci.com

A-V Search Hysteresis (AVSH) is a feature available in dual-chamber pacemakers designed to allow intrinsic conduction that might otherwise be masked by continuous pacing (i.e., pacing at an AV Delay that is shorter than the patient's P-R interval). AVSH may be useful for patients with exercise-dependent or intermittent AV nodal block. During normal AV nodal function, this feature temporarily allows intrinsic AV conduction to exceed the programmed AV Delay, thereby encouraging intrinsic AV conduction and reducing ventricular pacing. This may improve hemodynamic performance and increase device longevity due to a reduced number of ventricular paces. Reducing the amount of RV pacing in pacemaker patients: 1) moderately reduces the risk of developing persistent atrial fibrillation,<sup>1</sup> and 2) may reduce the progression to heart failure.<sup>2</sup>

### How AVSH Works

Programmable parameters associated with AV Delay and AVSH are described in Table 1. When the AVSH feature is enabled, the AV Delay (either fixed or Dynamic) is periodically lengthened for up to 8 consecutive cardiac cycles to search for intrinsic P-R intervals that are longer than the programmed AV Delay. The AV Delay is lengthened by the programmed percentage AV Increase, and once increased, will remain extended as long as ventricular sensing is occurring. The pacemaker will revert to the programmed paced AV Delay following the first ventricular pace at the Hysteresis AV Delay, or when the 8-cycle search window expires without sensing intrinsic ventricular activity.

Figure 1 illustrates the operation of AVSH. In this example, the device meets the programmed AVSH Search Interval criteria by consecutively pacing in the ventricle for 32 cycles. At this point, the AV Delay is lengthened by 100% (the programmed AV Increase) in search of intrinsic P-R activity. During the 1<sup>st</sup> cycle, the intrinsic P-R interval is longer than the Hysteresis AV Delay of 400 ms, so the ventricle remains paced. During cycles 2-17, because the intrinsic P-R interval is less than the Hysteresis AV Delay, ventricular pacing is inhibited to allow for intrinsic conduction. Pacing resumes on the 18th cycle because the P-R interval is once again longer than the Hysteresis AV Delay. At this point, the AV Delay returns to its programmed value, and a new Search Interval count begins.




Figure 1. Example of A-V Search Hysteresis operation.

## Activating AVSH

Although significant ventricular pacing would be expected for patients with more severe AV block, AVSH may provide an opportunity to encourage AV conduction and thereby reduce ventricular pacing for some patients with 1<sup>st</sup> degree or 2<sup>nd</sup> degree AV block.

Figure 2 displays the ZOOM<sup>®</sup>LATITUDE<sup>®</sup> programmer screen used to activate AVSH in an ALTRUA<sup>®</sup> pacemaker. With this programming, the device will allow the AV Delay to reach, but never exceed the maximum of 400 ms.

**Current programmed AV Delay parameters**

Parameter	Present	Change
Dynamic AV Delay	On	
Maximum Delay	220	ms
Minimum Delay	100	ms
Sensed AV Offset	-30	ms

**Current programmed AVSH parameters, including how often a search is conducted and the amount AV Delay will be lengthened during the search**

Parameter	Present	Change
AV Search Hysteresis		
Search Interval	32	cycles
AV Increase	100	%

Figure 2. ALTRUA Brady Parameters programmer screen.

An ALTRUA Counters report is shown in Figure 3. Since the previous follow-up visit, the device has paced in the ventricle 40% of the time, and has conducted 35 successful searches out of 39 search attempts.

Counter	Value	Since Last Reset
Paced and Sensed		
A-sensed / V-sensed	0 %	0
A-sensed / V-paced	0 %	0
A-paced / V-sensed	60 %	3.1M
A-paced / V-paced	40 %	2.1M
Atrial Paced	100 %	5.2M
Atrial Sensed	0 %	0
Ventricular Paced	40 %	2.1M
Ventricular Sensed	60 %	3.1M
A-Tachy Response		
Mode Switches	0 %	0
Total Time		0.0 min
Maximum Time		0.0 min
Average Time		0.0 min
Ectopic Beats		
PACs		0
Single or Double PVCs		0
Three or More PVCs		0
Atrial Tachy Detections		0
Ventricular Tachy Detections		0
Ventricular Interval Variation		
Variation 0 <= 10 %		9
Variation 11 <= 20 %		0
Variation 21 <= 30 %		0
Variation > 30 %		0
Rate Hysteresis		
Searches		0
Successful Searches		0
AV Hysteresis		
Searches		39
Successful Searches		35
Pacemaker Wenckebach Counters		0

Figure 3. Counters report from an ALTRUA pacemaker with AVSH On.\*

\* Individual symptoms, situations, circumstances, and results may vary.

**Table 1. Programmable Parameters Associated with A-V Search Hysteresis**

Programmable Parameters of Interest	Description	Programmable Values
<b>AV Delay</b>	Period from the beginning of an atrial event (either intrinsic or paced) to the paced ventricular event	10–300 ms in 10 ms increments for ALTRUA 20/ 40 series, INSIGNIA I Plus/ AVT/Ultra, PULSAR MAX II, PULSAR MAX, and PULSAR pacemakers 10–400 ms in 10 ms increments for ALTRUA 50/60 series pacemakers Nominal = 150 ms
<b>Dynamic AV Delay</b>	Mimics normal AV nodal function by adjusting AV Delay in response to rate changes	Off, On ➤ Nominal = On (ALTRUA™, and INSIGNIA® pacemakers) ➤ Nominal = Off ( PULSAR® MAX II, PULSAR MAX, and PULSAR pacemakers)
<b>Maximum Delay</b>	Longest Dynamic AV Delay allowed; will be applied at the lower rate limit	➤ 20–300 ms in 10 ms increments for ALTRUA 20/40 series, INSIGNIA I Plus/ AVT/Ultra, PULSAR MAX II, PULSAR MAX, and PULSAR pacemakers ➤ 20–400 ms in 10 ms increments for ALTRUA 50/60 series pacemakers Nominal = 150 ms
<b>Minimum Delay</b>	Shortest Dynamic AV Delay allowed; will be applied at the maximum tracking rate	10–290 ms in 10 ms increments Nominal = 80 ms
<b>AV Search Interval</b>	Activates AV Search Hysteresis and controls how often an AV search (up to 8 cycles long) will be conducted	OFF, 32, 64, 128, 256, 512, 1024 cycles Nominal = Off
<b>AV Increase</b>	Determines how much the AV Delay (either standard or dynamic) will be lengthened during a search cycle.	10%–100% in 10% increments Nominal = 30%

### Considerations for Extending AV Delay

While the use of AVSH may be beneficial in reducing unnecessary RV pacing for some patients, long AV intervals ( $\geq 250$  ms) should be used with caution. Physicians should evaluate the patient and weigh the potential benefit of promoting intrinsic conduction against the potential risk of hemodynamic compromise, such as pacemaker syndrome and diastolic mitral regurgitation.

<sup>1</sup>Sweeney, MO, Bank, AJ, Nsah, E, et. al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus node disease. *N Engl J Med.* 2007; 357: 1000-1008.

<sup>2</sup>Sweeney, MO, Hellkamp AS, Ellenbogen KA, et. al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. *Circulation.* 2003;107: 2932-2937.